FDA supplemental approval: Metformin Hydrochloride (Labeling)

AI Summary

This is a U.S. FDA supplemental approval action for a labeling change to metformin hydrochloride extended-release tablets (500 mg and 1 g) manufactured by Aurobindo Pharma, approved on 11 August 2026. The record documents the regulatory action and product details but contains no clinical trial results, efficacy data, or safety outcomes.

Plain-language summary

FDA supplemental approval of labeling changes for metformin hydrochloride extended-release tablets; this is a regulatory action record, not a clinical trial, and does not contain efficacy or safety data.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This is a regulatory action documenting approval of labeling changes. Clinicians should refer to the approved label for prescribing information, contraindications, warnings, and dosing; this record itself does not provide clinical guidance or comparative efficacy data.

Caveats

• This record contains no clinical trial results, efficacy data, safety study outcomes, or comparative benefit information.
• The specific labeling changes approved are not detailed in this record; the actual label document must be consulted.
• No adverse event data, trial data, or preclinical supporting evidence is provided in this regulatory record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.